Axel Hauschild, MD, PhD, University Hospital Schleswig-Holstein

Dr Vogel on Updated OS Data for Frontline Camrelizumab Plus Rivoceranib in Unresectable HCC

Dr Ramalingam on Osimertinib Post-Chemoradiotherapy in Unresectable, Stage III, EGFR-Mutated NSCLC

First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC

Addition of Atezolizumab to Chemotherapy and Bevacizumab Does Not Yield Benefit in Ovarian Cancer